Introduction
Some 50 different lysosomal disorders are known in humans (LSDs). They result from the defective function of a specific protein, which leads ultimately to the progressive accumulation within the lysosome of either undegraded substrate(s) or catabolic products that are unable to escape from this organelle. Most disorders are inherited in an autosomal recessive manner and the disease process is generally progressive and unremitting.
Lysosomes are present in all nucleated cells. They form part of a complex intracellular recycling system involved in the degradation of large macromolecules. This process is achieved in a stepwise manner by removal of terminal residues by a series of lysosomal enzymes, usually exohydrolases, and the released monomeric units are either transported or diffuse out of the lysosome. Approximately 75 different lysosomal enzymes (including glucosidases, lipases, proteases and nucleases) are involved in these degradative processes; since many of the substrates are complex lipids which are not water soluble, cofactors or activators may also be involved in enzyme-substrate interactions. Other proteins may be involved in protecting enzymes from being degraded themselves in this proteolytic environment. Lysosomal enzymes have maximum activity at an acid pH, and in the lysosome this is maintained by an energy-dependent proton pump. A useful property of these enzymes is the fact that although they are highly specific towards the structure and linkage of the terminal moiety on a complex macromolecule, the overall structure may not be important. It is therefore possible to measure lysosomal enzyme activities using a variety of relatively simple water-soluble substrates incorporating coloured or fluorescent groups. Such assays are commonly used for diagnostic studies.
Defects in lysosomal enzymes, cofactors or transport proteins may all give rise to specific lysosomal storage disorders and these can be classed conveniently according to the type(s) of storage material accumulating. In many cases, because lysosomal enzymes may act on several different substrates that share the same terminal residue, a complex storage pattern may result.
The lysosomal disorders, like many other metabolic diseases, show a remarkably varied clinical phenotype. In some patients, the presentation may be in utero or the newborn period, whereas in others, even with the same enzyme deficiency (but probably a different genetic mutation), onset may be in late adulthood. However, for most patients the onset of symptoms is in the first months or years of life following an often unremarkable and apparently normal early development. The first signs may be some slowing of development and other neurological signs; in other patients some organomegaly or a dysmorphic facial appearance may be noted. Recognition of these clinical signs will assist in the selection of appropriate diagnostic tests. In this review those disorders that can and often do present in the neonatal period will be highlighted. A very simple classification of lysosomal storage disorders is given in Table 1 , including reported neonatal presentation. For a comprehensive review of lysosomal structure and function the reader is guided to the excellent text edited by Applegarth [1] .
Clinical presentation Hydrops fetalis
Hydrops fetalis is known to be caused by a wide variety of fetal, placental and maternal disorders. Fetal mortality is high and it is a diagnostic challenge to ensure that those disorders associated with a recurrent risk of hydrops are identified. Table 2 lists some of the lysosomal disorders that have been associated with this presentation which have been extensively reviewed [2, 3] .
When faced with a hydropic fetus what features might suggest a diagnosis of a LSD? A history of recurrent episodes of non-immune hydrops fetalis is important as would be the presence of parental consanguinity. Detailed anatomical examination by ultrasound should attempt to diagnose placental and fetal abnormalities. Fetal echocardiography should be performed by an experienced operator to exclude congenital heart lesions and a fetal karyotype should be carried out to exclude aneuploidy. Cell-free fluid should be analysed for metabolite excretion (oligosaccharides and glycosaminoglycans) and a culture established for subsequent enzyme assay. Investigations on the mother are also indicated and should include maternal blood testing for antibody screening as well as serological testing for infectious disease.
Fetal blood sampling has a very limited place in the diagnosis of an LSD, as the volume that can be removed is so small. It may however be indicated to check for fetal anaemia, haemoglobin variants or other causes of haemolytic disease.
The fetal and neonatal mortality rate for nonimmune hydrops fetalis is very high [4] and a detailed physical and pathological examination of the placenta, fetus or neonate is essential in suspected cases of LSD. In an LSD, the placenta may appear pale and bulky to gross examination [5] and histology either by light microscopy or electron microscopy may confirm the presence of lysosomal vacuolation [6, 7] . In cases where no amniotic fluid has been obtained a placental cell line from a piece of chorion should be established for subsequent enzyme analysis. Often the presence of severe hydrops makes identification of the specific dysmorphic features (see later) associated with a LSD very difficult to appreciate. In addition the fetus may be macerated or aborted at a very early stage of the pregnancy making physical examination very difficult. In those infants who survive until late into the pregnancy or who are live-born a careful physical and radiological examination is required and this is described in the next section.
Dysmorphism
In general, the disorders that can present with hydrops fetalis (Table 2 ) can also present in the newborn period with dysmorphism. Infants in the newborn period with a 'Hurler-like' phenotype ( Fig. 1 ) usually have mucolipidosis II (I-cell disease), infantile sialic acid storage disease or GM 1 -gangliosidosis. In mucopolysaccharidosis type I (Hurler syndrome) the physical appearance at birth is normal although other abnormalities such as inguinal herniae [8] or extensive Mongolian spots [9] may be seen in affected patients. Hepatosplenomegaly and arthrogryposis may also be detected in the affected fetus.
Other disorders may have a more specific dysmorphic presentation; for example, infants with severe infantile Gaucher disease may present with a colloidian membrane [10] . Table 1 highlights other more specific presentations of which one or two deserve highlighting. DS -dermatan sulphate, HS -heparin sulphate, KS -keratin sulphate, HA -hyaluronic acid, SA -sialic acid, WBC -white blood cell, CVB -chorion villus biopsy, AF -amniotic fluid, GAGs -glycosaminoglycans, Oligos -oligosaccharides. 1. Low activity in CVB -caution re: contamination with maternal decidua. 2. Always do fetal sexing as some aunaffected female fetuses will have very low enzyme results. 3. Difficult because of cross-reactivity from other sulphatases. 4. UDP-N-Acetylglucosamine:lysosomal enzyme N-acetylglucosaminyl-l-phosphotransferase.
Other clinical presentations
A significant number of infants with NiemannPick disease type C (NPC) will present with a form of neonatal hepatitis [11] . In this group of patients death from liver failure can occur, but those that survive may not develop other features of the disease for many years.
Cardiomyopathy in the newborn period is a rare presentation of a LSD (it is more common in infants with disorders of intermediary metabolism), but should not be overlooked. Glycogen storage disease type II (Pompe disease) [12] and mucopolysaccharidoses [13] can present in this way.
Radiology
The radiological abnormalities associated with LSDs are known as dysostosis multiplex [14] . These defects in remodelling are usually not present in the neonatal period but become progressively more obvious during the first year or two of life. Different radiological abnormalities may be seen in specific disorders and this is illustrated by the characteristic findings seen in mucolipidosis II (I-cell disease). This condition is caused by a failure to target lysosomal enzymes to the organelle resulting from a deficiency of mannose-6-phosphate phosphotransferase activity, the enzyme necessary for post-translational modification of the enzymes to allow them to be targeted to lysosomes. Clinically, there is usually severe dysmorphism ( Fig. 1) with the additional finding of pronounced gingival hyperplasia (Fig. 2) . The radiological abnormalities are present from birth and include osteopenia, periosteal cloaking, neonatal or in-utero fractures and dysharmonic epiphyseal ossification [15] .
Diagnosis
Before considering the specific tests required for accurate diagnosis in individual cases, it is appropriate to consider a simple test that may help the diagnostic process. Storage phenomena may be seen in peripheral blood cells (Fig. 3) or bone marrow aspirates (Fig. 4) and an ultrastructural study of these tissues can be helpful [16] . Specific diagnosis usually requires a urine and blood sample. Urinary glycosaminoglycans and oligosaccharide excretion patterns should be analysed and specific enzyme assays will be required for definitive diagnosis (Table 1) . For some disorders e.g. Niemann-Pick disease type C more complicated diagnostic assays on cultured skin fibroblasts have to be performed and suspected cases should be discussed with the local metabolic laboratory.
Specific biochemical confirmation must be pursued in all suspected cases, as all these disorders are genetic. Prenatal testing is available for the vast majority and the method of choice is indicated in Table 1 .
In those patients in whom a diagnosis of an LSD is strongly suspected but initial biochemical investigations are negative, more invasive procedures such as organ biopsy may be indicated. The gold standard for diagnosis remains the demonstration of lysosomal storage at an ultrastructural level [17] . It is important to remember that some other disorders (especially if associated with hydrops fetalis) may mimic an LSD.
Treatment
For most disorders palliative care is all that can be offered and the prognosis for disorders presenting in the newborn period is particularly poor as this usually indicates a severe variant of the disease in question. Significant advances have however been made with this group of disorders [18] . These include bone marrow transplantation, direct enzyme replacement and substrate deprivation therapy. A common theme with therapy for these disorders that can affect the brain is the need for early diagnosis before the onset of irreversible damage. It is ironic that those conditions producing the most dramatic neonatal presentation may ultimately be the most treatable because of their likely earlier diagnosis.
Conclusions
Individually LSDs are rare. As a group, however, they have a prevalence similar to phenylketonuria in most communities [19, 20] and present a complex and challenging problem. Neonatal presentation is common and although treatment for the majority remains unsatisfactory developments over the next decade are likely to result in more effective therapies as well as the possible introduction of newborn screening [21, 22] for LSDs. 
